Merck, Foundation Medicine to build companion diagnostics for Keytruda
MedCity News | May 24, 2018
Drugs that target genetic abnormalities in cancer patients regardless of what specific tumor they have is an emerging trend in oncology drug development. But one challenge is identifying those patients, whose genetic anomalies may be exceedingly rare. With that in mind, drugmaker Merck & Co. and diagnostics maker Foundation Medicine announced Thursday a collaboration to develop companion diagnostics for Merck’s drug Keytruda in patients with microsatellite instability-high (MSI-H) and mismatch repair deficiency (dMMR).